Early this week, clinical-stage biopharmaceutical company Enterome announced that the first patient was dosed in a Phase 1/2 clinical trial. The SPENCER trial will evaluate EO2401 as a potential treatment…
Those diagnosed with paraganglioma-pheochromocytoma, squamous cell carcinoma of the skin (cSCC), adrenocortical carcinoma (ACC), and carcinoma of unknown primary (CUP) may soon have an additional option for treatment. According to…
An article in CURE® describes two extremely rare types of tumors: paraganglioma and pheochromocytoma. One in three thousand individuals may have either or both of these tumors. The symptoms accompanying…
The 2019 Pheo Para Conference Upstate New York Biotech Accelerator, Syracuse, NY Are you a pheochromocytoma or paraganglioma patient? Well don’t miss this important patient event. At this conference, pheochromocytoma…
Pheochromocytoma and Paraganglioma Pheochromocytoma refers to a type of tumor that arises from chromaffin cells. They normally occur in the adrenal medulla. However, 10% of these tumors occur outside of this…
According to a story from globenewswire.com, the company Progenic Pharmaceuticals recently reported the the U.S. Food and Drug Administration has recently approved the company's product iobenguane I 131 (AZEDRA). This…
According to a story from news-medical.net, the results of a recent research trial demonstrate that the radiation therapy drug AZEDRA (ultratrace iobenguane I131) is an effective and safe treatment option…
5th Annual International Symposium on Pheochromocytoma "Working Together Today for a Better Tomorrow" This event will be an opportunity for patients and medical professionals to learn about the latest research…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
